Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Chadi Nabhan

Showing results (21-30 of 199) with videos related to

Pageof 20
Sort By:
JAMA Oncology|May 26, 2018
Fulfillment of Postmarketing Requirements to the FDA for Therapies Granted Oncology Indications Between 2011 and 2016Marjorie Zettler, Chadi Nabhan
JAMA Oncology|June 8, 2018
BiosimilarsSandeep Parsad, Chadi Nabhan
Leukemia & Lymphoma|March 28, 2012
Diffuse large B-cell lymphoma: is there a place for autologous hematopoietic stem cell transplant in first remission in the era of chemo-immunotherapy?Chadi Nabhan, Jayesh Mehta
Leukemia & Lymphoma|April 28, 2016
Use of class I histone deacetylase inhibitor romidepsin in combination regimensAdam Petrich, Chadi Nabhan
Journal of the National Comprehensive Cancer Network : JNCCN|October 5, 2016
Ambulatory Oncology Operations: Strategies to Alleviate ComplexityChadi Nabhan, Sandeep Parsad
The Oncologist|January 21, 2018
Two Doctors, One Patient, and a Common GoalChadi Nabhan, Jeremy Topin
Clinical Lymphoma, Myeloma & Leukemia|October 4, 2016
Interim PET Scans in Diffuse Large B-Cell Lymphoma: Is It Ready for Prime Time?Maital Bolshinsky, Chadi Nabhan
The Journal of the American Osteopathic Association|July 18, 2012
Sister Mary Joseph nodule from prostate cancerKimberly Kruczek, Chadi Nabhan
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 27, 2026
Should We Call Every Cancer a Rare Cancer?Chadi Nabhan, Vivek Subbiah
Clinical Medicine Insights. Oncology|April 19, 2011
The emerging role of ofatumumab in the treatment of chronic lymphocytic leukemiaChadi Nabhan, Neil E Kay
Pageof 20

Showing results (21-30 of 199) with videos related to

Sort By:
Pageof 20
JAMA Oncology|May 26, 2018
Fulfillment of Postmarketing Requirements to the FDA for Therapies Granted Oncology Indications Between 2011 and 2016Marjorie Zettler, Chadi Nabhan
JAMA Oncology|June 8, 2018
BiosimilarsSandeep Parsad, Chadi Nabhan
Leukemia & Lymphoma|March 28, 2012
Diffuse large B-cell lymphoma: is there a place for autologous hematopoietic stem cell transplant in first remission in the era of chemo-immunotherapy?Chadi Nabhan, Jayesh Mehta
Leukemia & Lymphoma|April 28, 2016
Use of class I histone deacetylase inhibitor romidepsin in combination regimensAdam Petrich, Chadi Nabhan
Journal of the National Comprehensive Cancer Network : JNCCN|October 5, 2016
Ambulatory Oncology Operations: Strategies to Alleviate ComplexityChadi Nabhan, Sandeep Parsad
The Oncologist|January 21, 2018
Two Doctors, One Patient, and a Common GoalChadi Nabhan, Jeremy Topin
Clinical Lymphoma, Myeloma & Leukemia|October 4, 2016
Interim PET Scans in Diffuse Large B-Cell Lymphoma: Is It Ready for Prime Time?Maital Bolshinsky, Chadi Nabhan
The Journal of the American Osteopathic Association|July 18, 2012
Sister Mary Joseph nodule from prostate cancerKimberly Kruczek, Chadi Nabhan
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 27, 2026
Should We Call Every Cancer a Rare Cancer?Chadi Nabhan, Vivek Subbiah
Clinical Medicine Insights. Oncology|April 19, 2011
The emerging role of ofatumumab in the treatment of chronic lymphocytic leukemiaChadi Nabhan, Neil E Kay
Pageof 20